KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得

Nivolumab plus Ipilimumab versus Lenvatinib or Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: CheckMate 9DW Japanese Subgroup Analysis.

Masatoshi Kudo, Atsushi Hiraoka, Kazushi Numata, Tatsuya Yamashita, Masayuki Kurosaki, Tadashi Namisaki, Shuhei Hige, Yoshito Itoh, Satoshi Mochida, Tetsuya Hosaka, Norio Akuta, Tomokazu Kawaoka, Takuya Genda, Satoshi Kobayashi, Sawako Uchida-Kobayashi, Yuting Lu, Tatsuya Ogata, Maria Jesus Jimenez Exposito, Masafumi Ikeda

Liver Cancer 15(3) 381-393

PMID42338692
PMCIDPMC13286555
DOI10.1159/000548300
发表日期2026-06-24
摘要

摘要

INTRODUCTION: In the preplanned interim analysis of the phase 3 CheckMate 9DW trial, first-line nivolumab plus ipilimumab demonstrated significant overall survival (OS) benefit versus lenvatinib or sorafenib (hazard ratio [HR] = 0.79; 95% confidence interval [CI]: 0.65-0.96; p = 0.018) in patients with unresectable hepatocellular carcinoma (HCC). We present outcomes in Japanese patients from this trial. METHODS: Patients with unresectable HCC without prior systemic therapy were randomized 1:1 to receive nivolumab (1 mg/kg) plus ipilimumab (3 mg/kg) every 3 weeks (up to 4 doses, then nivolumab 480 mg every 4 weeks) or investigator's choice of lenvatinib or sorafenib. The primary endpoint was OS. Secondary endpoints included objective response rate (ORR) and duration of response (DOR) per blinded independent central review (BICR); safety was an exploratory endpoint. RESULTS: Fifty-six Japanese patients were randomized to nivolumab plus ipilimumab (n = 25) and lenvatinib or sorafenib (n = 31). After a median follow-up of 35.8 months (range: 28.2-45.3), median OS was not reached (NR) (95% CI: 16.9 months to not estimable [NE]) with nivolumab plus ipilimumab and 32.0 months (95% CI: 20.9-NE) with lenvatinib or sorafenib (HR = 0.64 [95% CI: 0.27-1.50]); 24- and 36-month OS rates were 70% versus 63% and 64% versus 40%, respectively. ORR per BICR with nivolumab plus ipilimumab was 56% (95% CI: 35-76) versus 16% (95% CI: 6-34) with lenvatinib or sorafenib. Median DOR was NR (95% CI: NE) and 11.1 months (95% CI: 6.4-NE), respectively. Grade 3/4 treatment-related adverse events occurred in 50% versus 65% of patients, respectively. There were no treatment-related deaths among Japanese patients. CONCLUSION: Consistent with the global population, first-line nivolumab plus ipilimumab showed clinically meaningful improvement in OS and ORR versus lenvatinib or sorafenib in Japanese patients with unresectable HCC, along with manageable safety. These results support nivolumab plus ipilimumab as a potential new first-line treatment for unresectable HCC in Japan.

KM 提取结果

3 个 Figure · 3 个 KM 面板

进入结果中心
KM Figure1 个面板

Fig. 2.

Fig. 2. Kaplan-Meier estimate of OS in all randomized Japanese patients. HR from an unstratified Cox proportional hazard model for nivolumab plus ipilimumab over lenvatinib or sorafenib. Tick marks indicate censored data. CI, confidence interval; HR, hazard ratio; IPI, ipilimumab; LEN, lenvatinib; mo, months; NE, not evaluable; NIVO, nivolumab; NR, not reached; OS, overall survival; SOR, sorafenib.

Fig._2

OS

Fig. 2. · Panel Fig._2

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Fig._2 是同一 Fig. 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure1 个面板

Fig. 3.

Fig. 3. Kaplan-Meier estimate of DOR in all randomized Japanese patients with a confirmed objective response. Kaplan-Meier estimate based on all patients with a confirmed complete or partial response per BICR using Response Evaluation Criteria in Solid Tumors, version 1.1 ( n = 14 in the nivolumab plus ipilimumab group; n = 5 in the lenvatinib or sorafenib group). Tick marks indicate censored data. BICR, blinded independent central review; CI, confidence interval; DOR, duration of response; HR, hazard ratio; IPI, ipilimumab; LEN, lenvatinib; mo, months; NE, not evaluable; NIVO, nivolumab; NR, not reached; SOR, sorafenib.

DOR_in_Japanese_patients

Duration of response

Fig. 3. · Panel DOR_in_Japanese_patients

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel DOR_in_Japanese_patients 是同一 Fig. 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 1:flat topline artifact曲线 2:very low support曲线 2:extreme jump
查看结果
KM Figure1 个面板

Fig. 4.

Fig. 4. Kaplan-Meier estimate of PFS in all randomized Japanese patients. PFS assessed by BICR per Response Evaluation Criteria in Solid Tumors, version 1.1. HR from an unstratified Cox proportional hazard model for nivolumab plus ipilimumab over lenvatinib or sorafenib. Tick marks indicate censored data. BICR, blinded independent central review; CI, confidence interval; HR, hazard ratio; IPI, ipilimumab; LEN, lenvatinib; mo, months; NE, not evaluable; NIVO, nivolumab; NR, not reached; PFS, progression-free survival; SOR, sorafenib.

KM

PFS

Fig. 4. · Panel KM

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel KM 是同一 Fig. 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1.Fig. 1. CONSORT diagram.
非 KM Figure